Results of two consecutive phase II trials of patients with systemic AL amyloidosis treated with high-dose melphalan after induction and mobilisation chemotherapy

被引：0
|
作者：
Schonland, S. O. [1 ]
Bochtler, T. [1 ]
Perz, J. [1 ]
Hansberg, M. [1 ]
Mangatter, A. [1 ]
Ho, A. D. [1 ]
Goldschmidt, H. [1 ]
Hegenbart, U. [1 ]
机构：
[1] Univ Heidelberg, Dept Internal Med, Div Hematol Oncol Rheumatol, Amyloidosis Ctr, D-6900 Heidelberg, Germany
来源：
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2010年 / 17卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [1] LONGTERM FOLLOW-UP OF PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS TREATED WITH HIGH-DOSE MELPHALAN AFTER INDUCTION AND MOBILIZATION CHEMOTHERAPY
    Schonland, S. O.
    Bochtler, T.
    Hansberg, M.
    Mangatter, A.
    Perz, J. B.
    Hundemer, M.
    Ho, A. D.
    Goldschmidt, H.
    Hegenbart, U.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 36 - 36
  • [2] Long-term follow-up of patients with systemic AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation after induction and mobilisation chemotherapy
    Schonland, S. O.
    Bochtler, T.
    Hansberg, M.
    Mangatter, A.
    Perz, J. B.
    Ho, A. D.
    Goldschmidt, H.
    Hegenbart, U.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S65 - S66
  • [3] Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis
    Schonland, Stefan
    Hegenbart, Ute
    Benner, Axel
    Perz, Jolanta
    Bochtler, Tilmann
    Beimler, Joerg
    Zeier, Martin
    Kristen, Arnt
    Ho, Anthony D.
    Goldschmidt, Hartmut
    BLOOD, 2009, 114 (22) : 1320 - 1321
  • [4] High-dose melphalan and autologous stem cell transplantation after VAD chemotherapy for systemic light chain (AL) amyloidosis
    Perz, JB
    Schoenland, S
    Hundemer, M
    Linke, RP
    Ho, AD
    Goldschmidt, H
    BONE MARROW TRANSPLANTATION, 2004, 33 : S159 - S159
  • [5] MELPHALAN-DEXAMETHASONE IN PATIENTS WITH AL AMYLOIDOSIS NOT ELIGIBLE FOR HIGH-DOSE MELPHALAN THERAPY
    Schoenland, S. O.
    Dietrich, S.
    Hegenbart, U.
    Bochtler, T.
    Kristen, A. V.
    Goldschmidt, H.
    Ho, A. D.
    Schoenland, S. O.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 260 - 261
  • [6] High-dose melphalan chemotherapy with autologous stem cell transplantation in patients with AL amyloidosis: No increased mortality using induction and mobilization chemotherapy.
    Schonland, SO
    Hegenbart, U
    Dengler, JB
    Benner, A
    Hundemer, M
    Bochtler, T
    Ho, AD
    Goldschmidt, H
    BLOOD, 2005, 106 (11) : 464B - 465B
  • [7] Phase II trial of high-dose dexamethasone for untreated patients with primary-systemic amyloidosis (AL).
    Gertz, MA
    Lacy, MQ
    Lust, JA
    Greipp, PR
    Witzig, TE
    Kyle, RA
    BLOOD, 1998, 92 (10) : 107A - 107A
  • [8] Phase II trial of high-dose dexamethasone for previously treated primary systemic amyloidosis
    Gertz, MA
    Lacy, MQ
    Lust, JA
    Greipp, PR
    Witzig, TE
    Kyle, RA
    AMYLOID AND AMYLOIDOSIS 1998, 1999, : 172 - 174
  • [9] AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation
    van Gameren, II
    Hazenberg, BPC
    Jager, PL
    Smit, JW
    Vellenga, E
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2002, 9 (03): : 165 - 174
  • [10] High-dose melphalan followed by autologous stem cell transplantation in patients with primary systemic (AL) amyloidosis
    Knop, S
    Lengerke, C
    Hebart, H
    Kanz, L
    Einsele, H
    BONE MARROW TRANSPLANTATION, 2004, 33 : S165 - S165
12345